The Committee will meet to discuss Zevra Therapeutics (ZVRA) New Drug Application (NDA) for Arimoclomol as an orally delivered, first-in-class treatment for Niemann-Pick disease type C (NPC) in a meeting being held on August 2 at 9 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics to Report Second Quarter 2024 Financial Results
- Zevra Therapeutics Announces Key Agreement Updates and Stock Offering
- Zevra Therapeutics Approaches Key FDA Review and PDUFA Date
- Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
- Zevra Therapeutics announces FDA GeMDAC meeting to review arimoclomol